TY - JOUR
T1 - Adverse cardiodynamic effects of vasopressin not avoided by selective intra-arterial administration
AU - Sirinek, Kenneth R.
AU - Thomford, Neil R.
AU - Pace, William G.
PY - 1977/6
Y1 - 1977/6
N2 - In this study, lysine-vasopressin, administered either as a continuous, intravenous infusion (1 unit/kg/hour) or as a selective infusion into the superior mesenteric artery (0.2 unit/minute), produced equal (↓25%), significant (p < 0.05), and sustained (60 minute) reductions in portal pressure. Compared to intravenous administration, selective intra-arterial infusion of vasopressin resulted in similar reductions in cardiac output (↓38%), myocardial contractility (↓23%), and coronary flow (↓53%). Since these adverse cardiodynamic effects were not avoided by selective intra-arterial infusion, it would appear that administration of vasopressin as a continuous infusion through a peripheral vein remains the most rapid and practical method of administering the drug.
AB - In this study, lysine-vasopressin, administered either as a continuous, intravenous infusion (1 unit/kg/hour) or as a selective infusion into the superior mesenteric artery (0.2 unit/minute), produced equal (↓25%), significant (p < 0.05), and sustained (60 minute) reductions in portal pressure. Compared to intravenous administration, selective intra-arterial infusion of vasopressin resulted in similar reductions in cardiac output (↓38%), myocardial contractility (↓23%), and coronary flow (↓53%). Since these adverse cardiodynamic effects were not avoided by selective intra-arterial infusion, it would appear that administration of vasopressin as a continuous infusion through a peripheral vein remains the most rapid and practical method of administering the drug.
UR - http://www.scopus.com/inward/record.url?scp=0017704407&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017704407&partnerID=8YFLogxK
M3 - Article
C2 - 860202
AN - SCOPUS:0017704407
VL - 81
SP - 723
EP - 728
JO - Surgery (United States)
JF - Surgery (United States)
SN - 0039-6060
IS - 6
ER -